Low- and high-dose radioiodine ablation for low-/intermediate-risk differentiated thyroid cancer in China: A large randomized clinical trial

被引：7
|
作者：
Dong, Ping [1 ]
Wang, Li [2 ]
Qu, Yuan [3 ]
Huang, Rui [1 ]
Li, Lin [1 ]
机构：
[1] Sichuan Univ, West China Hosp, Dept Nucl Med, Guoxue Alley 37, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Pancreat Surg, Chengdu, Peoples R China
[3] Tongji Univ, East Hosp, Dept Med Imaging, Shanghai, Peoples R China
来源：
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2021年 / 43卷 / 04期
基金：
中国国家自然科学基金;
关键词：
China; differentiated thyroid cancer; prospective study; radioiodine; remnant ablation;
D O I：
10.1002/hed.26594
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Background: To determine whether 1.1 GBq radioiodine therapy is as effective as 3.7 GBq for ablation in Chinese patients with differentiated thyroid cancer (DTC). Methods: In this single-center randomized study, we compared the successful radioiodine ablation rates of 1.1 GBq and 3.7 GBq for patients with DTC. Results: At 6-8 months after radioiodine ablation, there were 95 (39%) patients in the 1.1 GBq group and 79 (32%) patients in the 3.7 GBq group with thyroid hormone withdrawal (THW), and ablation success rates were 84% versus 80%, respectively; and 149 (61%) patients in the 1.1 GBq group and 169 (68%) patients in the 3.7 GBq group without THW, and ablation success rates were 89% versus 90%, respectively. In total, the ablation was successful in 412 (87%) of the 474 patients, and it was similar between the two groups. Conclusions: Low-dose radioiodine ablation was as effective as high dose in Chinese DTC patients.
引用
收藏
页码：1311 / 1320
页数：10
相关论文
共 50 条
  • [41] A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine
    Greenberg, Peter L.
    Garcia-Manero, Guillermo
    Moore, Michael
    Damon, Lloyd
    Roboz, Gail
    Hu, Kuolung
    Yang, Allen S.
    Franklin, Janet
    LEUKEMIA & LYMPHOMA, 2013, 54 (02) : 321 - 328
  • [42] Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease
    Walser, Eric
    Nance, Anne
    Ynalvez, Leslie
    Yong, Shan
    Aoughsten, Jacqueline S.
    Eyzaguirre, Eduardo J.
    Williams, Stephen B.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 30 (03) : 401 - 409
  • [43] The role of neck ultrasound in the follow-up of low- and intermediate-risk papillary thyroid cancer
    Lopes, Sara Gomes de Campos
    Ferreira, David Nuno Dias Silva
    Fernandes, Vera Adriana Ribeiro
    Marques, Helena Manuela da Costa Cardoso
    Pereira, Ricardo Fernando da Silva Santos
    Monteiro, Ana Margarida Carvalho
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (04): : 481 - 488
  • [44] Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma
    Ahn, D.
    Lee, G. J.
    Sohn, J. H.
    BRITISH JOURNAL OF SURGERY, 2020, 107 (06) : 687 - 694
  • [45] Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer
    Abe, Koichiro
    Ishizaki, Umiko
    Ono, Toshihiro
    Horiuchi, Kiyomi
    Kanaya, Kazuko
    Sakai, Shuji
    Okamoto, Takahiro
    ANNALS OF NUCLEAR MEDICINE, 2020, 34 (02) : 144 - 151
  • [46] Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer
    Koichiro Abe
    Umiko Ishizaki
    Toshihiro Ono
    Kiyomi Horiuchi
    Kazuko Kanaya
    Shuji Sakai
    Takahiro Okamoto
    Annals of Nuclear Medicine, 2020, 34 : 144 - 151
  • [47] Longitudinal regret after treatment for low- and intermediate-risk prostate cancer
    Hurwitz, Lauren M.
    Cullen, Jennifer
    Kim, Daniel J.
    Elsamanoudi, Sally
    Hudak, Jane
    Colston, Maryellen
    Travis, Judith
    Kuo, Huai-Ching
    Rice, Kevin R.
    Porter, Christopher R.
    Rosner, Inger L.
    CANCER, 2017, 123 (21) : 4252 - 4258
  • [48] Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer
    Pacini, Furio
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (06): : 379 - 381
  • [49] Pure Hypofractionated Radiotherapy for the Treatment of Low- to Intermediate-Risk Prostate Cancer
    Stephens, R.
    Gopaul, D.
    Panjwani, D.
    Lock, M.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S732 - S732
  • [50] Current focal therapies for the treatment of low- and intermediate-risk prostate cancer
    Malorgio, Antonio
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 592 - 594
12345